We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Lattice Biologics, Sunnybrook Launch Collaboration

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Lattice Biologics, Sunnybrook Launch Collaboration"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Lattice Biologics is pleased to announce it has entered into an Industry Sponsored Collaboration Agreement with Sunnybrook Research Institute (“SRI”) in Toronto, Ontario titled, “Conditional Reprogramming of Epithelial Cells to Determine Mechanisms of Resistance and Drug Sensitivity” (the “Study”).  The purpose of the Study is to develop new research methods, including the creation of new instruments to make cellular measurements, and the validation of methods to determine mechanisms of resistance and drug sensitivity.  The successful identification of such new methods would lead to commercialization of high content screening (HCS) chemosensitivity testing for cancer patients.

“We are extremely pleased to be working with such a prestigious partner as Sunnybrook Research Institute to develop a personalized approach for cancer diagnostics,” states Guy Cook, Chief Executive Officer of Lattice Biologics Ltd.

“Lattice Biologic’s ECM technology is revolutionary in its unparalleled ability to accurately recreate complex tumor microenvironments because it allows us to grow biopsies from patients’ own cancer tumors in the laboratory, subject the tumors to multiple anti-cancer agents, and observe the resulting behaviors all while sustaining natural conditions. 

“This will provide a never-before-seen understanding of how individual patients’ tumors respond to specific treatments, allowing physicians to prescribe anti-cancer treatments with new accuracy.  This level of personalized medicine will change the entire cancer treatment game.

“Most people you meet have already felt the devastating sting of cancer somewhere in their life,” continued Cook.  “I am personally motivated to improve outcomes by advancing diagnostic techniques as my father passed from lung cancer in 1981, my aunt from pancreatic cancer in 1982, and my sister – also from pancreatic cancer – in 1991.  As such, the opportunity to contribute to Dr. Andrews’ cutting edge diagnostic research with our ECM technology is both humbling and personally fulfilling.”